✦ LIBER ✦

Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine

✍ Scribed by P. Bore; N. Lena; A. M. Imbert; R. Favre; J. P. Cano; G. Meyer; Y. Carcassonne

Book ID: 104715293
Publisher: Springer
Year: 1986
Tongue: English
Weight: 453 KB
Volume: 17
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00306749

No coin nor oath required. For personal study only.

✦ Synopsis

High-dose methotrexate (HD-MTX) infusions associated with vindesine (VDS) have been used in the treatment of head and neck cancer. In a previous study, VDS was shown to increase the apparent plasma clearance of MTX. We have studied the MTX hydroxylation process in the presence of VDS. Different routes of administration have been tested (IV pushes and 24-h or 36-h infusions). A radioimmunoassay has been developed to measure 7-OH-MTX. The defined protocols enabled us to show that VDS influences not only the pharmacokinetic behavior of methotrexate but also its hydroxylation, which is decreased in presence of VDS.

📜 SIMILAR VOLUMES

Methotrexate-vindesine association in th

Methotrexate-vindesine association in the treatment of head and neck cancer Influence of vindesine on methotrexate's pharmacokinetic behavior

✍ N. Lena; A. M. Imbert; T. Pignon; R. Favre; G. Meyer; J. P. Cano; Y. Carcassonne 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 360 KB

A randomized prospective comparison of i

A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin and a methotrexate combination in head and neck cancer

✍ R.C. DeConti; D. Schoenfeld 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 207 KB

Vinblastine, methotrexate, bleomycin, in

Vinblastine, methotrexate, bleomycin, in the management of head and neck cancer

✍ C. Vanhaelen; M. Bertrand; R. De Jager; Y. Kenis 📂 Article 📅 1979 🏛 Elsevier Science ⚖ 275 KB

A randomized prospective comparison of m

A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer

✍ Steven E. Vogl; David A. Schoenfeld; Barry H. Kaplan; Harvey J. Lerner; Paul F. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 1020 KB

Combination chemotherapy with methotrexate, bleomycin, and cis-diamminedichloroplatinum (11) was compared to weekly therapy with methotrexate alone in a randomized prospective trial in 163 patients with recurrent or metastatic squamous cancer of the mucous membranes of the head and neck. The combina

A phase II study of cisplatin and contin

A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer

✍ Eduardo Tellez-Bernal; Gonzalo Recondo; Thierry Guillot; Mohamed Benhamed; Chris 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 2 views

The chemotherapeutic treatment of recurrent and/or metastatic squamous cell carcinoma (SCC) of the head and neck (H & N) has a very dismal prognosis, with survival usually not exceeding 1 year. Reported objective response rates vary between 3% and 70%. This difference appears largely attributable to

A phase II study of piritrexim in combin

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer

✍ Everett E. Vokes; Isaiah W. Dimery; Charlotte D. Jacobs; Daniel Karp; Arturo Mol 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 2 views

Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day